Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Apr 12

PMID 32276377

Citations 31

Authors

Eric Owusu Obeng

Isabella Rusciano

Maria Vittoria Marvi

Antonietta Fazio

Stefano Ratti

Matilde Yung Follo

Jie Xian

Lucia Manzoli

Anna Maria Billi

Sara Mongiorgi

Giulia Ramazzotti

Lucio Cocco

Affiliations

Soon will be listed here.

Abstract

Phosphoinositides (PI) form just a minor portion of the total phospholipid content in cells but are significantly involved in cancer development and progression. In several cancer types, phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P] and phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P] play significant roles in regulating survival, proliferation, invasion, and growth of cancer cells. Phosphoinositide-specific phospholipase C (PLC) catalyze the generation of the essential second messengers diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (InsP) by hydrolyzing PtdIns(4,5)P. DAG and InsP regulate Protein Kinase C (PKC) activation and the release of calcium ions (Ca) into the cytosol, respectively. This event leads to the control of several important biological processes implicated in cancer. PLCs have been extensively studied in cancer but their regulatory roles in the oncogenic process are not fully understood. This review aims to provide up-to-date knowledge on the involvement of PLCs in cancer. We focus specifically on PLCβ, PLCγ, PLCδ, and PLCε isoforms due to the numerous evidence of their involvement in various cancer types.

Citing Articles

Plasma membrane and nuclear phosphatidylinositol 4,5-bisphosphate signalling in cancer.

Chytla A, Rattay S, Akgul B, Sztacho M Lipids Health Dis. 2025; 24(1):39.

PMID: 39915829 PMC: 11800418. DOI: 10.1186/s12944-025-02452-6.

Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling.

Nunes J, Ijsselsteijn M, Abdelaal T, Ursem R, van der Ploeg M, Giera M Nat Methods. 2024; 21(10):1796-1800.

PMID: 39210066 PMC: 11466816. DOI: 10.1038/s41592-024-02392-6.

Proteomic landscape of epithelial ovarian cancer.

Qian L, Zhu J, Xue Z, Zhou Y, Xiang N, Xu H Nat Commun. 2024; 15(1):6462.

PMID: 39085232 PMC: 11291745. DOI: 10.1038/s41467-024-50786-z.

Assessing the associations of 1,400 blood metabolites with major depressive disorder: a Mendelian randomization study.

Dong T, Wang X, Jia Z, Yang J, Liu Y Front Psychiatry. 2024; 15:1391535.

PMID: 38903637 PMC: 11187323. DOI: 10.3389/fpsyt.2024.1391535.

Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling.

Abdoul-Azize S, Hami R, Riou G, Derambure C, Charbonnier C, Vannier J Nat Commun. 2024; 15(1):4557.

PMID: 38811530 PMC: 11136999. DOI: 10.1038/s41467-024-48818-9.

References

Fili C, Malagola M, Follo M, Finelli C, Iacobucci I, Martinelli G . Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res. 2013; 19(12):3297-308. DOI: 10.1158/1078-0432.CCR-12-3540. View

Koss H, Bunney T, Behjati S, Katan M . Dysfunction of phospholipase Cγ in immune disorders and cancer. Trends Biochem Sci. 2014; 39(12):603-11. DOI: 10.1016/j.tibs.2014.09.004. View

Faenza I, Bavelloni A, Fiume R, Lattanzi G, Maraldi N, Gilmour R . Up-regulation of nuclear PLCbeta1 in myogenic differentiation. J Cell Physiol. 2003; 195(3):446-52. DOI: 10.1002/jcp.10264. View

Xian J, Obeng E, Ratti S, Rusciano I, Marvi M, Fazio A . Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes. Cells. 2020; 9(3). PMC: 7140618. DOI: 10.3390/cells9030697. View

Villalobo A, Berchtold M . The Role of Calmodulin in Tumor Cell Migration, Invasiveness, and Metastasis. Int J Mol Sci. 2020; 21(3). PMC: 7037201. DOI: 10.3390/ijms21030765. View

Sorli S, Bunney T, Sugden P, Paterson H, Katan M . Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants. Oncogene. 2004; 24(1):90-100. DOI: 10.1038/sj.onc.1208168. View

Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H . Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009; 16(2):161-71. PMC: 2744338. DOI: 10.1016/j.ccr.2009.05.018. View

KELLEY G, Reks S, Ondrako J, Smrcka A . Phospholipase C(epsilon): a novel Ras effector. EMBO J. 2001; 20(4):743-54. PMC: 145421. DOI: 10.1093/emboj/20.4.743. View

Mongiorgi S, Follo M, Clissa C, Giardino R, Fini M, Manzoli L . Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics. Curr Top Microbiol Immunol. 2012; 362:235-45. DOI: 10.1007/978-94-007-5025-8_11. View

10.

Fu L, Qin Y, Xie D, Hu L, Kwong D, Srivastava G . Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res. 2007; 67(22):10720-6. DOI: 10.1158/0008-5472.CAN-07-2411. View

11.

Monteith G, Prevarskaya N, Roberts-Thomson S . The calcium-cancer signalling nexus. Nat Rev Cancer. 2017; 17(6):367-380. DOI: 10.1038/nrc.2017.18. View

12.

Follo M, Faenza I, Piazzi M, Blalock W, Manzoli L, McCubrey J . Nuclear PI-PLCβ1: an appraisal on targets and pathology. Adv Biol Regul. 2013; 54:2-11. DOI: 10.1016/j.jbior.2013.11.003. View

13.

Raimondi C, Chikh A, Wheeler A, Maffucci T, Falasca M . A novel regulatory mechanism links PLCγ1 to PDK1. J Cell Sci. 2012; 125(Pt 13):3153-63. PMC: 3434861. DOI: 10.1242/jcs.100511. View

14.

Allen V, Swigart P, Cheung R, Cockcroft S, Katan M . Regulation of inositol lipid-specific phospholipase cdelta by changes in Ca2+ ion concentrations. Biochem J. 1997; 327 ( Pt 2):545-52. PMC: 1218828. DOI: 10.1042/bj3270545. View

15.

Poli A, Ratti S, Finelli C, Mongiorgi S, Clissa C, Lonetti A . Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). FASEB J. 2017; 32(2):681-692. DOI: 10.1096/fj.201700690R. View

16.

Ratti S, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Billi A . Nuclear inositide signaling and cell cycle. Adv Biol Regul. 2017; 67:1-6. DOI: 10.1016/j.jbior.2017.10.008. View

17.

Falasca M, Logan S, Lehto V, Baccante G, Lemmon M, Schlessinger J . Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. 1998; 17(2):414-22. PMC: 1170392. DOI: 10.1093/emboj/17.2.414. View

18.

Ramazzotti G, Faenza I, Follo M, Fiume R, Piazzi M, Giardino R . Nuclear phospholipase C in biological control and cancer. Crit Rev Eukaryot Gene Expr. 2011; 21(3):291-301. DOI: 10.1615/critreveukargeneexpr.v21.i3.50. View

19.

Liu W, Cai M, Zheng C, Wang J, Zhao X . Phospholipase Cγ1 connects the cell membrane pathway to the nuclear receptor pathway in insect steroid hormone signaling. J Biol Chem. 2014; 289(19):13026-41. PMC: 4036317. DOI: 10.1074/jbc.M113.547018. View

20.

Liu W, Liu X, Wang L, Zhu B, Zhang C, Jia W . PLCD3, a flotillin2-interacting protein, is involved in proliferation, migration and invasion of nasopharyngeal carcinoma cells. Oncol Rep. 2017; 39(1):45-52. PMC: 5783603. DOI: 10.3892/or.2017.6080. View